Molecular pathology and personalized medicine: The dawn of a new era in companion diagnostics—practical considerations about companion diagnostics for non-small-cell-lung-cancer
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
Companion diagnostics (CDx) have become a major tool in molecular pathology and assist in therapy decisions in an increasing number of various cancers. Particularly, the developments in lung cancer have been most impressing in the last decade and consequently lung cancer mutation testing and molecular profiling has become a major business of diagnostic laboratories. However, it has become difficult to decide which biomarkers are currently relevant for therapy decisions, as many of the new biomarkers are not yet approved as therapy targets, remain in the status of clinical studies, or still have not left the experimental phase. The current review is focussed on those markers that do have current therapy implications, practical implications arising from the respective companion diagnostics, and thus is focused on daily practice.
Details
Original language | English |
---|---|
Pages (from-to) | 1-14 |
Number of pages | 14 |
Journal | Journal of Personalized Medicine |
Volume | 6 |
Issue number | 1 |
Publication status | Published - 15 Jan 2016 |
Peer-reviewed | Yes |
Externally published | Yes |
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- ALK, Companion diagnostics, EGFR, FISH, KRAS, Lung cancer